Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹6,738 Cr
verified against source
Revenue YoY
29%
reported change
EBITDA
₹2,137 Cr
latest reported figure
Source
nse xbrl
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Dr. Reddy's delivered a strong Q1 FY24 with consolidated revenue of INR 6,738 crore (+29% YoY) and EBITDA margin of 31.7%, driven by robust U.S. generics growth (+69% YoY to $389M) including lenalidomide, Mayne Pharma integration, and market share gains. India business grew 40% (high single-digit adjusted), while Russia surged 77% YoY. Management maintained long-term EBITDA margin guidance of ~25% (currently above due to lenalidomide) and expects U.S. momentum to continue. Key risks include volatility in Russia, potential price erosion normalization, and execution risk in building the India innovation pipeline.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated 25% as the sustainable EBITDA margin level, though near-term will be higher due to lenalidomide.
- Expects sustained strong performance in North America generics, including base business growth and new product launches.
- Plans to sign tens of licensing deals for innovative products in India, with meaningful revenue contribution from FY2025.
- Biosimilar R&D currently ~20% of total R&D; expected to grow progressively with pipeline advancement.
Risks flagged
- Significant portion of U.S. growth attributed to lenalidomide; agreement ends January 2026, creating uncertainty beyond.
- Russia business grew 77% but on a low base; currency and geopolitical risks remain high.
- Top-5 aspiration relies on signing and commercializing multiple innovative products; timeline and uptake uncertain.
- Current lower price erosion may be temporary; management noted model hasn't changed, implying potential reversion.
Key quotes
- We are not going to chase acquisitions just because we have cash on the balance sheet.
- I don't enjoy when we are growing on the expense of others. I actually want the supply to be there for the patient.
- The way to do that for us is by launching innovation.
Research modules